Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients
Go back to Ligand (LGND), Glaxo (GSK) Receive FDA Approval for PROMACTA in HCV Patients| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 52.67 +1.52 (2.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $51.15 | 52 Week High | $45.58 | |||
| Open | $51.40 | 52 Week Low | $37.82 | |||
| Day High | $52.70 | P/E | N/A | |||
| Day Low | $51.35 | EPS | $0.00 | |||
| Volume | 2,696,488 | |||||
| LIGAND PHARMA (NASDAQ: LGND) | Delayed: 289.12 +1.53 (0.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $287.59 | 52 Week High | $139.79 | |||
| Open | $291.02 | 52 Week Low | $82.07 | |||
| Day High | $294.61 | P/E | 672.37 | |||
| Day Low | $282.25 | EPS | $0.43 | |||
| Volume | 142,957 | |||||
